{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T03:28:37Z","timestamp":1787801317417,"version":"build-2784847793"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T00:00:00Z","timestamp":1579737600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T00:00:00Z","timestamp":1579737600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s11523-020-00696-z","type":"journal-article","created":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T06:02:50Z","timestamp":1579759370000},"page":"47-54","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Association Between Glutathione-S-Transferase Gene Polymorphisms and Responses to Tyrosine Kinase Inhibitor Treatment in Patients with Chronic Myeloid Leukemia: A Meta-analysis"],"prefix":"10.1007","volume":"15","author":[{"given":"Nari","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Min","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ha Young","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Min","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0278-2563","authenticated-orcid":false,"given":"Hye Sun","family":"Gwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,23]]},"reference":[{"key":"696_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7\u201334.","journal-title":"CA Cancer J Clin"},{"key":"696_CR2","unstructured":"National Comprehensive Cancer Network. Chronic myeloid leukemia (Version 1.2018). https:\/\/www.nccn.org\/patients\/guidelines\/cml\/files\/assets\/common\/downloads\/files\/cml.pdf. Accessed 20 Aug 2019."},{"issue":"Suppl 2","key":"696_CR3","doi-asserted-by":"publisher","first-page":"S241","DOI":"10.1007\/s00277-015-2314-2","volume":"94","author":"M H\u00f6glund","year":"2015","unstructured":"H\u00f6glund M, Sandin F, Simonsson B. Epidemiology of chronic myeloid leukaemia: an update. Ann Hematol. 2015;94(Suppl 2):S241\u20137.","journal-title":"Ann Hematol"},{"key":"696_CR4","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.6004\/jnccn.2018.0071","volume":"16","author":"JP Radich","year":"2018","unstructured":"Radich JP, Deininger M, Abboud CN, Altman JK, Berman E, Bhatia R, et al. Chronic myeloid leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2018;16:1108\u201335.","journal-title":"J Natl Compr Cancer Netw"},{"key":"696_CR5","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1124\/jpet.105.084145","volume":"315","author":"A Arora","year":"2005","unstructured":"Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther. 2005;315:971\u20139.","journal-title":"J Pharmacol Exp Ther"},{"key":"696_CR6","first-page":"461","volume":"11","author":"K Sailaja","year":"2010","unstructured":"Sailaja K, Surekha D, Rao DN, Rao DR, Vishnupriya S. Association of the GSTP1 gene (Ile105Val) polymorphism with chronic myeloid leukemia. Asian Pac J Cancer Prev. 2010;11:461\u20134.","journal-title":"Asian Pac J Cancer Prev"},{"key":"696_CR7","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/clpt.2014.176","volume":"96","author":"A Davies","year":"2014","unstructured":"Davies A, Giannoudis A, Zhang JE, Austin G, Wang L, Holyoake TL, et al. Dual glutathione-S-transferase-\u03b81 and -\u03bc1 gene deletions determine imatinib failure in chronic myeloid leukemia. Clin Pharmacol Ther. 2014;96:694\u2013703.","journal-title":"Clin Pharmacol Ther"},{"key":"696_CR8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s12032-014-0047-z","volume":"31","author":"Y Kassogue","year":"2014","unstructured":"Kassogue Y, Quachouh M, Dehbi H, Quessar A, Benchekroun S, Nadifi S. Effect of interaction of glutathione S-transferases (T1 and M1) on the hematologic and cytogenetic responses in chronic myeloid leukemia patients treated with imatinib. Med Oncol. 2014;31:47.","journal-title":"Med Oncol"},{"key":"696_CR9","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/s10517-014-2732-5","volume":"158","author":"VA Ovsepyan","year":"2014","unstructured":"Ovsepyan VA, Luchinin AS, Zagoskina TP. Role of glutathione-S-transferase M1 (GSTM1) and T1 (GSTT1) genes in the development and progress of chronic myeloid leukemia and in the formation of response to imatinib therapy. Bull Exp Biol Med. 2014;158:242\u20135.","journal-title":"Bull Exp Biol Med"},{"key":"696_CR10","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.mgene.2017.02.006","volume":"12","author":"W Al-Achkar","year":"2017","unstructured":"Al-Achkar W, Moassass F, Aroutiounian R, Harutyunyan T, Liehr T, Wafa A. Effect of glutathione S-transferase mu 1 (GSTM1) gene polymorphism on chronic myeloid leukemia risk and Imatinib treatment response. Meta Gene. 2017;12:113\u20137.","journal-title":"Meta Gene"},{"key":"696_CR11","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s12041-017-0819-2","volume":"96","author":"SM Makhtar","year":"2017","unstructured":"Makhtar SM, Husin A, Baba AA, Ankathil R. Association of GSTM1, GSTT1 and GSTP1 Ile105Val polymorphisms with clinical response to imatinib mesylate treatment among Malaysian chronic myeloid leukaemia patients. J Genet. 2017;96:633\u20139.","journal-title":"J Genet"},{"key":"696_CR12","doi-asserted-by":"publisher","first-page":"e0182901","DOI":"10.1371\/journal.pone.0182901","volume":"12","author":"AV Lavrov","year":"2017","unstructured":"Lavrov AV, Ustaeva OA, Adilgereeva EP, Smirnikhina SA, Chelysheva EY, Shukhov OA, et al. Copy number variation analysis in cytochromes and glutathione S-transferases may predict efficacy of tyrosine kinase inhibitors in chronic myeloid leukemia. PLoS ONE. 2017;12:e0182901.","journal-title":"PLoS ONE"},{"key":"696_CR13","doi-asserted-by":"crossref","first-page":"e00717","DOI":"10.1002\/mgg3.717","volume":"7","author":"G Rostami","year":"2019","unstructured":"Rostami G, Assad D, Ghadyani F, Hamid M, Karami A, Jalaeikhoo H, et al. Influence of glutathione S-transferases (GSTM1, GSTT1, and GSTP1) genetic polymorphisms and smoking on susceptibility risk of chronic myeloid leukemia and treatment response. Mol Genet Genomic Med. 2019;7:e00717.","journal-title":"Mol Genet Genomic Med"},{"key":"696_CR14","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1038\/s41375-018-0321-8","volume":"33","author":"JH Park","year":"2019","unstructured":"Park JH, Woo YM, Youm EM, Hamad N, Won HH, Naka K, et al. HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia. Leukemia. 2019;33:1439\u201350.","journal-title":"Leukemia"},{"key":"696_CR15","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1158\/2326-6066.CIR-17-0462","volume":"6","author":"H Ureshino","year":"2018","unstructured":"Ureshino H, Shindo T, Kojima H, Kusunoki Y, Miyazaki Y, Tanaka H, et al. Allelic polymorphisms of KIRs and HLAs predict favorable responses to tyrosine kinase inhibitors in CML. Cancer Immunol Res. 2018;6:745\u201354.","journal-title":"Cancer Immunol Res"},{"key":"696_CR16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev.pharmtox.45.120403.095857","volume":"45","author":"JD Hayes","year":"2005","unstructured":"Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. Annu Rev Pharmacol Toxicol. 2005;45:51\u201388.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"696_CR17","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1016\/j.bbagen.2012.11.019","volume":"1830","author":"PG Board","year":"2013","unstructured":"Board PG, Menon D. Glutathione transferases, regulators of cellular metabolism and physiology. Biochim Biophys Acta. 2013;1830:3267\u201388.","journal-title":"Biochim Biophys Acta"},{"issue":"Suppl 2","key":"696_CR18","doi-asserted-by":"publisher","first-page":"S141","DOI":"10.1007\/s00277-015-2322-2","volume":"94","author":"M Baccarani","year":"2015","unstructured":"Baccarani M, Castagnetti F, Gugliotta G, Rosti G. A review of the European LeukemiaNet recommendations for the management of CML. Ann Hematol. 2015;94(Suppl 2):S141\u20137.","journal-title":"Ann Hematol"},{"key":"696_CR19","unstructured":"Wells GA, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.htm. Accessed 16 Aug 2019."},{"key":"696_CR20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.","journal-title":"Trials"},{"key":"696_CR21","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539\u201358.","journal-title":"Stat Med"},{"key":"696_CR22","first-page":"719","volume":"22","author":"N Mantel","year":"1959","unstructured":"Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719\u201348.","journal-title":"J Natl Cancer Inst"},{"key":"696_CR23","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177\u201388.","journal-title":"Control Clin Trials"},{"key":"696_CR24","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u201334.","journal-title":"BMJ"},{"key":"696_CR25","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.","journal-title":"PLoS Med"},{"key":"696_CR26","first-page":"2267","volume-title":"Cancer, principles and practice of oncology","author":"BJ Druker","year":"2005","unstructured":"Druker BJ, Lee SJ. Chronic leukemias. In: Devit VT, Hellman S, Rosenberg SA, editors. Cancer, principles and practice of oncology. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 2267\u2013304."},{"key":"696_CR27","doi-asserted-by":"publisher","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27:6041\u201351.","journal-title":"J Clin Oncol."},{"key":"696_CR28","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1093\/annonc\/mdq201","volume":"21","author":"M Baccarani","year":"2010","unstructured":"Baccarani M, Dreyling M. Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21:165\u20137.","journal-title":"Ann Oncol."},{"key":"696_CR29","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872\u20134.","journal-title":"Blood."},{"key":"696_CR30","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","volume":"108","author":"M Baccarani","year":"2006","unstructured":"Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809\u201320.","journal-title":"Blood."},{"key":"696_CR31","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1038\/sj.onc.1209373","volume":"25","author":"CC McIlwain","year":"2006","unstructured":"McIlwain CC, Townsend DM, Tew KD. Glutathione S-transferase polymorphisms: cancer incidence and therapy. Oncogene. 2006;25:1639\u201348.","journal-title":"Oncogene"},{"key":"696_CR32","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/00008571-200210000-00006","volume":"12","author":"TM Ishimoto","year":"2002","unstructured":"Ishimoto TM, Ali-Osman F. Allelic variants of the human glutathione S-transferase P1 gene confer differential cytoprotection against anticancer agents in Escherichia coli. Pharmacogenetics. 2002;12:543\u201353.","journal-title":"Pharmacogenetics"},{"key":"696_CR33","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/tpj.2009.45","volume":"10","author":"AV Khrunin","year":"2010","unstructured":"Khrunin AV, Moisseev A, Gorbunova V, Limborska S. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J. 2010;10:54\u201361.","journal-title":"Pharmacogenomics J"},{"key":"696_CR34","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1007\/s00280-016-3173-9","volume":"78","author":"X Kong","year":"2016","unstructured":"Kong X, Li Z, Li X. GSTP1, GSTM1, and GSTT1 polymorphisms as predictors of response to chemotherapy in patients with breast cancer: a meta-analysis. Cancer Chemother Pharmacol. 2016;78:1163\u201373.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"15","key":"696_CR35","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1089\/ars.2017.7134","volume":"27","author":"E Hatem","year":"2017","unstructured":"Hatem E, El Banna N, Huang ME. Multifaceted roles of glutathione and glutathione-based systems in carcinogenesis and anticancer drug resistance. Antioxid Redox Signal. 2017;27(15):1217\u201334.","journal-title":"Antioxid Redox Signal"},{"key":"696_CR36","first-page":"381","volume":"19","author":"S Phuthong","year":"2018","unstructured":"Phuthong S, Settheetham-Ishida W, Natphopsuk S, Ishida T. Genetic polymorphism of the glutathione S-transferase pi 1 (GSTP1) and susceptibility to cervical cancer in human papilloma virus infected Northeastern Thai women. Asian Pac J Cancer Prev. 2018;19:381\u20135.","journal-title":"Asian Pac J Cancer Prev"},{"key":"696_CR37","doi-asserted-by":"publisher","first-page":"7482","DOI":"10.12659\/MSM.912373","volume":"24","author":"H Wang","year":"2018","unstructured":"Wang H, Gao X, Zhang X, Gong W, Peng Z, Wang B, et al. Glutathione S-transferase gene polymorphisms are associated with an improved treatment response to cisplatin-based chemotherapy in patients with non-small cell lung cancer (NSCLC): a meta-analysis. Med Sci Monit. 2018;24:7482\u201392.","journal-title":"Med Sci Monit"},{"key":"696_CR38","doi-asserted-by":"publisher","first-page":"e67589","DOI":"10.1371\/journal.pone.0067589","volume":"8","author":"J Ge","year":"2013","unstructured":"Ge J, Tian AX, Wang QS, Kong PZ, Yu Y, Li XQ, et al. The GSTP1 105Val allele increases breast cancer risk and aggressiveness but enhances response to cyclophosphamide chemotherapy in North China. PLoS ONE. 2013;8:e67589.","journal-title":"PLoS ONE"},{"key":"696_CR39","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1007\/s00277-014-2050-z","volume":"93","author":"Q Xiao","year":"2014","unstructured":"Xiao Q, Deng D, Li H, Ye F, Huang L, Zhang B, et al. GSTT1 and GSTM1 polymorphisms predict treatment outcome for acute myeloid leukemia: a systematic review and meta-analysis. Ann Hematol. 2014;93:1381\u201390.","journal-title":"Ann Hematol"},{"key":"696_CR40","first-page":"1239","volume":"10","author":"S Garte","year":"2001","unstructured":"Garte S, Gaspari L, Alexandrie AK, Ambrosone C, Autrup H, Autrup JL, et al. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomark Prev. 2001;10:1239\u201348.","journal-title":"Cancer Epidemiol Biomark Prev"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-020-00696-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11523-020-00696-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-020-00696-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T01:16:04Z","timestamp":1611278164000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11523-020-00696-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,23]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["696"],"URL":"https:\/\/doi.org\/10.1007\/s11523-020-00696-z","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,23]]},"assertion":[{"value":"23 January 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No external funding was used in the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Nari Lee, Su Min Park, Jeong Yee, Ha Young Yoon, Ji Min Han, and Hye Sun Gwak declare that they have no conflict of interest that might be relevant to the contents of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}